文献速递药物不良反应与药物警戒

阿帕替尼:晚期胃癌及其他晚期癌症治疗综述

Apatinib: A Review in Advanced Gastric Cancer and Other Advanced Cancers.
PubMed 文献 · Drugs · 2018-01-01

阿帕替尼(rivoceranib)是一种选择性VEGFR-2酪氨酸激酶抑制剂,在中国获批用于晚期或转移性胃癌。本文综述其药理学特性及在化疗经治的晚期胃腺癌(含胃食管腺癌)及其他晚期癌症中的临床应用。作为三线或后续治疗,口服阿帕替尼较安慰剂显著延长中位无进展生存期和总生存期,安全性可控;其他实体瘤证据有限,需进一步长期药物警戒数据。

要点

  • 阿帕替尼是选择性VEGFR-2酪氨酸激酶抑制剂,中国获批用于晚期或转移性胃癌。
  • 在化疗经治的晚期胃癌或胃食管腺癌患者中,三线或后续治疗可显著延长PFS和OS。
  • 其他晚期实体瘤(NSCLC、乳腺癌、HCC等)证据有限,需进一步研究确认。

核心结论

  • 口服阿帕替尼作为三线或后续治疗,在化疗经治的中国晚期或转移性胃癌或胃食管腺癌患者中,较安慰剂显著延长中位无进展生存期和总生存期,且安全性可控。

研究设计与样本

  • 本文为综述,汇总阿帕替尼的药理学特性及在化疗经治的晚期胃腺癌(含胃食管腺癌)或其他晚期癌症患者中的临床使用证据。
  • 证据来源包括随机、双盲、多中心2期和3期试验,受试者为晚期或转移性胃癌或胃食管腺癌的中国患者。

主要发现

  • 在随机、双盲、多中心2期和3期试验中,口服阿帕替尼较安慰剂显著延长中位无进展生存期和总生存期。
  • 阿帕替尼在晚期或转移性胃癌或胃食管腺癌中国患者中安全性可控。
  • 有限证据支持阿帕替尼作为后续线治疗用于其他晚期或转移性实体瘤的中国患者,包括非小细胞肺癌、乳腺癌和肝细胞癌。

临床怎么用

  • 阿帕替尼可作为成人晚期胃腺癌或胃食管腺癌患者化疗后进展或复发的三线或后续治疗选择。
  • 对于其他晚期或转移性实体瘤(如非小细胞肺癌、乳腺癌、肝细胞癌),现有证据有限,使用需谨慎评估。

局限性

  • 需要进一步临床经验和长期药物警戒数据,以更明确地确定阿帕替尼的疗效和安全性,包括与其他化疗药物联合使用及其他类型晚期或转移性实体瘤的管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Apatinib [Aitan® (brand name in China)], also known as rivoceranib, is a novel, small molecule, selective vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor and is the second anti-angiogenic drug to be approved in China for the treatment of advanced or metastatic gastric cancer. This article summarizes the pharmacological properties of apatinib and reviews its clinical use in chemotherapy-experienced patients with advanced gastric adenocarcinoma, including gastroesophageal adenocarcinoma (GEA), or with other advanced cancers such as non-small cell lung cancer (NSCLC), breast cancer, gynaecological cancers, hepatocellular carcinoma (HCC), thyroid cancer and sarcomas. As third- or subsequent-line therapy, oral apatinib significantly prolonged median progression-free survival (PFS) and overall survival (OS) compared with placebo and had a manageable safety profile in Chinese patients with advanced or metastatic gastric cancer or GEA participating in randomized, double-blind, multicentre, phase 2 and 3 trials. More limited evidence also supports it use as subsequent-line treatment in Chinese patients with other advanced or metastatic solid tumours, including NSCLC, breast cancer and HCC. Further clinical experience and long-term pharmacovigilance data are required to more definitively establish the efficacy and safety profile of apatinib, including its use in combination with other chemotherapy agents and its role in the management of other types of advanced or metastatic solid tumours. In the meantime, given its convenient administration regimen and the limited treatment options and poor prognosis for patients with advanced or metastatic solid tumours, apatinib is an important, emerging treatment option for adult patients with advanced gastric adenocarcinoma or GEA who have progressed or relapsed after chemotherapy.

来源:Drugs,查看原文。版权归原作者所有。

引用

  1. Scott LJ. Apatinib: A Review in Advanced Gastric Cancer and Other Advanced Cancers. Drugs. 2018. PMID: 29663291. doi:10.1007/s40265-018-0903-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。